Department of Radiation Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India.
Department of Thoracic Surgery, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India.
Dis Esophagus. 2022 Mar 12;35(3). doi: 10.1093/dote/doab020.
Locoregional recurrences following surgery for esophageal cancers represent a significant clinical problem with no standard recommendations for management. We conducted this systematic review and meta-analysis with the objective of studying safety and efficacy of salvage radiotherapy in this setting. All prospective and retrospective cohort studies, which studied patients who developed locoregional recurrence following initial radical surgery for esophageal cancer and subsequently received salvage radiation therapy (RT)/chemoradiation with all relevant information regarding survival outcome and toxicity available, were included. The quality of eligible individual studies was assessed using the Newcastle-Ottawa Scale score for risk of bias. R package MetaSurv was used to obtain a summary survival curve from survival probabilities and numbers of at-risk patients collected at various time points and to test the overall heterogeneity using the I2 statistic. Thirty studies (27 retrospective, 3 prospective) published from 1995 to 2020 with 1553 patients were included. The median interval between surgery and disease recurrence was 12.5 months. The median radiation dose used was 60 Gy and 57% received concurrent chemotherapy. The overall incidence of acute grade 3/4 mucositis and dermatitis were 8 and 4%, respectively; grade 3/4 acute pneumonitis was reported in 5%. The overall median follow-up of all studies included was 27 months. The 1-, 2- and 3-year overall survival (OS) probabilities were 67.9, 35.9 and 30.6%, respectively. Factors which predicted better survival on multivariate analysis were good PS, lower group stage, node negativity at index surgery, longer disease-free interval, nodal recurrence (as compared to anastomotic site recurrence), smaller disease volume, single site of recurrence, RT dose >50 Gy, conformal RT, use of concomitant chemotherapy and good radiological response after radiotherapy. Salvage radiotherapy with or without concomitant chemotherapy for locoregional recurrences after surgery for esophageal cancer is safe and effective. Modern radiotherapy techniques may improve outcomes and reduce treatment-related morbidity.
手术后食管癌的局部区域复发是一个严重的临床问题,目前尚无标准的治疗建议。我们进行了这项系统评价和荟萃分析,旨在研究局部区域复发后进行挽救性放疗的安全性和有效性。所有前瞻性和回顾性队列研究,研究了初始根治性手术治疗食管癌后发生局部区域复发,随后接受挽救性放疗(RT)/放化疗的患者,并获得了所有与生存结果和毒性相关的信息,均被纳入。使用纽卡斯尔-渥太华量表(Newcastle-Ottawa Scale)评分评估合格个体研究的质量,以评估偏倚风险。使用 R 包 MetaSurv 从在不同时间点收集的生存概率和风险患者数量中获得汇总生存曲线,并使用 I2 统计量测试整体异质性。纳入了 1995 年至 2020 年发表的 30 项研究(27 项回顾性研究,3 项前瞻性研究),共纳入 1553 例患者。手术和疾病复发之间的中位间隔时间为 12.5 个月。使用的中位放疗剂量为 60Gy,57%的患者接受了同期化疗。急性 3/4 级黏膜炎和皮炎的总发生率分别为 8%和 4%;报告了 5%的 3/4 级急性肺炎。所有纳入研究的中位总随访时间为 27 个月。1、2 和 3 年的总生存率(OS)分别为 67.9%、35.9%和 30.6%。多因素分析预测生存更好的因素是良好的 PS、较低的组分期、指数手术时淋巴结阴性、无疾病间期较长、淋巴结复发(与吻合口复发相比)、疾病体积较小、单一部位复发、RT 剂量>50Gy、适形 RT、同期化疗和放疗后良好的放射学反应。对于手术后食管癌的局部区域复发,挽救性放疗联合或不联合同期化疗是安全有效的。现代放疗技术可能改善结果并降低治疗相关的发病率。